2021 Annual Meeting Biologics Access Pass-The Business of OrthoBiologics in Clinical Practice

Video Transcription

Video Summary

The speaker begins by thanking the individuals involved in organizing the program and describes the meeting as more of a celebration than a medical conference. They discuss the market for orthobiologics, estimating its worth at $4.5 to $10 billion, with a growing annual growth rate of 15 to 23 percent. The speaker explains that these therapies are in high demand due to the increasing incidence of osteoarthritis and patients' reluctance to undergo total joint replacements. They discuss the considerations and coding guidelines for using orthobiologics, emphasizing the need to consult with individual carriers regarding coverage and reimbursement. The speaker recommends using an advanced beneficiary notification for non-covered services and provides coding recommendations for viscosupplementation, platelet-rich plasma (PRP), bone marrow aspirate concentrate (BMAC), and adipose tissue treatments. They conclude by emphasizing the importance of knowing the regulations, being transparent, and documenting outcomes. No credits are mentioned.

Asset Caption

Dr. Louis McIntyre

Keywords

orthobiologics market

therapies in high demand

coding guidelines

coverage and reimbursement

documenting outcomes